GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GlaxoSmithKline (GSK) is conducting a clinical study titled ‘Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination With Dostarlimab in Pediatric and Young Adult Participants With Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR)’. The study aims to find the most tolerated dose of cobolimab and dostarlimab in children and young adults with advanced solid tumors, assess safety, manage side effects, and evaluate treatment effects.
The study tests two experimental drugs, Cobolimab and Dostarlimab, which are intended to treat pediatric and young adult cancer patients. The goal is to determine the optimal dosing and assess the safety and efficacy of this drug combination.
This interventional study is non-randomized and follows a sequential intervention model with no masking. The primary purpose is treatment, focusing on dose determination and expansion phases.
The study began on March 6, 2025, with its last update on August 6, 2025. These dates are crucial as they mark the progress and current status of the study, which is active but not recruiting participants.
For investors, this study could impact GSK’s stock performance as it progresses, especially if results show positive outcomes. The pharmaceutical industry, particularly competitors in oncology treatments, will be closely watching these developments.
The study is ongoing, with further details available on the ClinicalTrials portal.